Beijing Medisai Pharmaceutical Technology

Beijing Medisai Pharmaceutical Technology is a clinical-stage biopharmaceutical company based in Beijing, China, specializing in the discovery and development of innovative small molecule therapeutics. The company's primary focus lies in metabolic diseases, oncology, and autoimmune disorders, with a significant emphasis on addressing unmet needs in gout and hyperuricemia. Its lead program, MDS-002, is a highly selective URAT1 inhibitor currently undergoing Phase 2 clinical evaluation for the treatment of chronic gout. Medisai utilizes its internal research capabilities to build a robust pipeline of differentiated drug candidates aimed at both domestic and international markets. The company is strategically located in the Zhongguancun Life Science Park, leveraging the regional biotech ecosystem to accelerate its R&D efforts.